Clinical Trials Logo
  1. Home
  2. Cytomegalovirus Infection
  3. NCT03930615

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

Cytomegalovirus Infection Clinical Trial

Official title:
A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)

Clinical Trial Summary

The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It was hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03930615
Study type Interventional
Source Merck Sharp & Dohme LLC
Contact
Status Completed
Phase Phase 3
Start date June 21, 2019
Completion date March 16, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT00023036 - Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Terminated NCT01037712 - In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Phase 4
Completed NCT00370006 - Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT01552369 - CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Phase 4
Completed NCT00223925 - Maribavir for Prevention of CMV After Stem Cell Transplants Phase 2
Active, not recruiting NCT05085366 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Phase 3
Completed NCT01220895 - Alternate Donor Study of Pre-Emptive Cellular Therapy Phase 2
Completed NCT00942305 - Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients Phase 2
Completed NCT00373412 - Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge Phase 1
Completed NCT05105048 - A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 Phase 1
Completed NCT00386412 - TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant Phase 2
Completed NCT03382405 - Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults Phase 1
Completed NCT02454699 - Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers Phase 1
Active, not recruiting NCT03910478 - Dried Blood Spot Testing of CMV Detection in HCT Recipients N/A
Completed NCT01354301 - Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Phase 4
Active, not recruiting NCT01473849 - Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients N/A
Completed NCT00880789 - Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus Phase 1
Completed NCT00817908 - Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients N/A
Completed NCT00273143 - A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients. Phase 1